Anti-CD47 monoclonal antibodies exert minimal apoptosis, no CDC, but affect ADCC. (A) TCL cells were incubated with the indicated antibodies at 10 µg/mL or 10 μM staurosporine (positive control) for 2 h and the percentage of live cells was quantified by flow cytometry. (B, C) CDC assay with 30% murine and human complement was performed in triplicate and % PI⁺ cells are reported. Rituximab and Raji cells were used as positive controls, whereas trastuzumab was used as negative control. (D) ADCC reporter assay measuring luminescence with murine FcγRIIIA-expressing Jurkat cells was performed in triplicate at an effector:target ratio of 25:1 with indicated antibodies. Human anti-CD3 mAb (OKT3) was used as positive control along with its isotype control, mIgG2aκ. Fold induction is relative to isotype control (mIgG1κ for B6H12 and mIgG2aκ for OKT3). Shown are mean values of technical triplicates with error bars representing SEM. *P < .05, **P < .01, ***P < .001, ****P < .0001 by 2-sided Welch t-test. (E) CFSE-labeled TCL cells were incubated with human-derived NK cells in the presence of indicated antibodies for 4 hours. Percentage of propidium iodide positive (% PI pos) (of CFSE⁺) cells was determined by flow cytometry and plotted. Rituximab and Raji cells were used as positive controls whereas trastuzumab was used as negative control. Shown are mean values of technical triplicates with error bars representing SEM. *P < .05, **P < .01, ***P < .001, ****P < .0001 by 2-sided Welch t test. SEM, standard error of the mean.